LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Fulgent Genetics Inc

Geschlossen

BrancheGesundheitswesen

22.43 2.23

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

21.74

Max

22.54

Schlüsselkennzahlen

By Trading Economics

Einkommen

-7.4M

-19M

Verkäufe

8.3M

82M

Gewinnspanne

-23.539

Angestellte

1,313

EBITDA

-3.5M

-15M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+14.98% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

124M

673M

Vorheriger Eröffnungskurs

20.2

Vorheriger Schlusskurs

22.43

Nachrichtenstimmung

By Acuity

50%

50%

167 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Fulgent Genetics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Sept. 2025, 23:56 UTC

Heiße Aktien

Stocks to Watch: FedEx, 22nd Century, Scholastic

18. Sept. 2025, 22:01 UTC

Wichtige Markttreiber

22nd Century Group Shares Gain on Debt Repayment, New Capital

18. Sept. 2025, 20:51 UTC

Akquisitionen, Fusionen, Übernahmen

UPS Terminates Plan to Buy Estafeta

18. Sept. 2025, 20:31 UTC

Ergebnisse

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18. Sept. 2025, 20:26 UTC

Ergebnisse

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18. Sept. 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Sept. 2025, 23:43 UTC

Market Talk

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18. Sept. 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

18. Sept. 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Cautious Mood -- Market Talk

18. Sept. 2025, 23:31 UTC

Market Talk

FedEx Says U.S. Demand Is Resilient -- Market Talk

18. Sept. 2025, 22:03 UTC

Ergebnisse

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18. Sept. 2025, 22:01 UTC

Ergebnisse

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18. Sept. 2025, 21:56 UTC

Ergebnisse

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18. Sept. 2025, 21:54 UTC

Ergebnisse

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18. Sept. 2025, 21:48 UTC

Ergebnisse

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18. Sept. 2025, 21:47 UTC

Ergebnisse

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18. Sept. 2025, 21:17 UTC

Ergebnisse

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18. Sept. 2025, 21:07 UTC

Ergebnisse

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18. Sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Sept. 2025, 20:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

18. Sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

18. Sept. 2025, 20:22 UTC

Akquisitionen, Fusionen, Übernahmen

UPS Cites Inability of All Closing Conditions to Be Satisfied

18. Sept. 2025, 20:22 UTC

Akquisitionen, Fusionen, Übernahmen

United Parcel Service Terminates Plan to Buy Estafeta

18. Sept. 2025, 20:20 UTC

Akquisitionen, Fusionen, Übernahmen

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18. Sept. 2025, 20:18 UTC

Ergebnisse

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18. Sept. 2025, 20:18 UTC

Ergebnisse

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18. Sept. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Sept. 2025, 20:07 UTC

Ergebnisse

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18. Sept. 2025, 20:03 UTC

Ergebnisse

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Peer-Vergleich

Kursveränderung

Fulgent Genetics Inc Prognose

Kursziel

By TipRanks

14.98% Vorteil

12-Monats-Prognose

Durchschnitt 25.33 USD  14.98%

Hoch 30 USD

Tief 21 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Fulgent Genetics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

2

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

17.32 / 19.04Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

167 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
help-icon Live chat